Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood Cancer Journal

Volumn 4, Issue 1, 2014, Pages

  Tan, P ^a   Wei, A ^a   Mithraprabhu, S ^a   Cummings, N ^a   Liu, H B ^a   Perugini, M ^b   Reed, K ^a   Avery, S ^a   Patil, S ^a   Walker, P ^a   Mollee, P ^c   Grigg, A ^d   D'Andrea, R ^b   Dear, A ^a   Spencer, A ^a  

^a MONASH UNIVERSITY   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

acute myeloid leukemia; azacitidine; epigenetic therapy; histone deacetylase inhibitor; myelodysplastic syndrome

Indexed keywords

AZACITIDINE; PANOBINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EPIGENETICS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GENE TARGETING; HEADACHE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HISTONE ACETYLATION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INFECTION; INJECTION SITE REACTION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERICARDIAL EFFUSION; PETECHIA; RASH; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84892413294     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.68     Document Type: Article

References (37)

1. Burnett A, Milligan D, Prentice A, Goldstone A, Mcmullin M, Hills R et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114-1124.
2. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
4. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
5. Thepot S, Itzykson R, Seegers V, Recher C, Quesnel B, Delaunay J et al. Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program. ASH Annual Meeting Abstracts 2009; 114: 843.
6. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al. Azacitidine for the treatment of patients with acute myeloid leukemia. Cancer 2012; 118: 1014-1022.
7. Agrawal-Singh S, Isken F, Agelopoulos K, Klein H-U, Thoennissen NH, Koehler G et al. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood 2012; 119: 2346-2357.
8. Maslak P, Chanel S, Camacho L, Soignet S, Pandolfi P, Guernah I et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2005; 20: 212-217.
9. Gore S, Baylin S, Sugar E, Carraway H, Miller C, Carducci M et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361.
10. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi S-H et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-2773.
11. Raffoux E, Cras A, Recher C, Boe? lle P-Y, de Labarthe A, Turlure P et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1: 34.
12. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308.
13. Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K et al. Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. ASH Annual Meeting Abstracts 2011; 118: 608.
14. Odenike O, Godley LA, Madzo J, Karrison T, Green M, Artz AS et al. A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. ASCO Meeting Abstracts 2011; 29(15-suppl): 6521.
15. Cameron EE, Bachman KE, Myo?ha?nen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
16. DeAngelo D, Spencer A, Bhalla K, Prince H, Fischer T, Kindler T et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628-1636.
17. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27: 1850-1856.
18. Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl Goldstein K, Cashen AF et al. A phase II study of 5 day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009; 84: 560-564.
19. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642.
20. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
21. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
22. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
23. Greenberg P, Cox C, Le Beau M. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 1997; 89: 2079-2088.
24. Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013; 90: 345-348.
25. Rigby L, Muscat A, Ashley D, Algar E. Methods for the analysis of histone H3 and H4 acetylation in blood. Epigenetics 2012; 7: 875-882.
26. Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol 2013; 162: 559-562.
27. Perugini M, Iarossi D, Kok C, Cummings N, Diakiw S, Brown A et al. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. Leukemia 2012; 27: 1588-1592.
28. Humphries R, Dover G, Young NS, Moore JG, Charache S, Ley T et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 1985; 75: 547.
29. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J et al. Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia. Nat Med 2007; 13: 730-735.
30. Zhou L, Ruvolo V, McQueen T, Chen W, Samudio I, Conneely O et al. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemiaassociated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 2012; 27: 1358-1368.
31. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
32. Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013; 98: 208-216.
33. Garcia-Manero G, Estey EH, Jabbour E, Kadia T, Estrov Z, Cortes J et al. Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities. ASH Annual Meeting Abstracts 2010; 116: 604.
34. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
35. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. Cancer Res 2006; 66: 6361.
36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
37. Deschler B, Ihorst G, Platzbecker U, Germing U, Ma?rz E, de Figuerido M et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013; 98: 208-216.